# US 2024/0218041 A1 · Molecular design of glucose sensors in glucose-responsive insulin analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0218041 A1
- Document ID: US20240218041A1
- Status: Published application
- Kind: A1
- Application number: 18/288,925
- Filed: 2022-05-03
- Published: 2024-07-04
- Earliest claimed: 2021-05-06
- Assignees: The Trustees of Indiana University
- Applicants: The Trustees of Indiana University
- Inventors: Michael A. WEISS; Mark A. JAROSINSKI
- Web page: https://patentgrep.com/patent/US20240218041A1

## CPC

- C07K 14/622: {at least 1 amino acid in D-form}
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 14/62: Insulins
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

A two-chain insulin analogue is provided containing (a) a B chain modified by the addition of a C-terminal diol element in combination with (b) a glucose-binding element attached to the A chain at or near its N terminus, optionally linked to a D-amino acid. A “flipped” set of insulin analogues wherein the A chain is modified by addition of an N-terminal diol element whereas the glucose-binding element is attached at or near the C terminus of the B chain is also provided. Compositions comprising such insulin analogues are used in methods of treating a patient with diabetes mellitus.

## Claims

### Claim 1

An insulin analogue comprising an insulin A chain and an insulin B chain,
said insulin A chain comprising either (a) a D-amino acid at position A1, (b) an L- or D-amino acid at A0 or (c) an L- or D amino acid at A−1 to which one or more glucose-binding elements is covalently linked, where residues A0 and A−1 represent optional N-terminal extensions of the A chain; and said insulin B chain contains one or more diol groups at or near the C terminus of the insulin B chain, optionally with the proviso that at least one of positions A0 and A1 is present and is a D amino acid.

### Claim 2 (depends on 1)

The insulin analogue of claim 1 wherein said glucose-binding element contains two or more boron atoms and is covalently linked to either (a) the side chain of an amino acid at positions A−1, A0 or A1 and/or (b) to the α-amino group of residues A−1, A0 or A1.

### Claim 3 (depends on 1)

The insulin analogue of claim 1 comprising 1 or 2 amino acids added to the N-terminus of the native insulin A chain.

### Claim 4 (depends on 3)

The insulin analogue of claim 3 wherein the N-terminal amino acid of said insulin A chain is glycine.

### Claim 5 (depends on 3)

The insulin analogue of claim 3 wherein said diol group is linked to a side chain of residues B26, B27, B28, B29, B30 or to C-terminal extension B31 or B31-B32.

### Claim 6 (depends on 3)

The insulin analogue of claim 3 wherein said diol group is a main chain diol, having the —COOH group of the C-terminal amino acid replaced with —CH2OH, optionally in combination with a side-chain modification of residues B26, B27, B28, B29, B30 or C-terminal extension B31 or B31-B32 residue with a diol bearing moiety.

### Claim 7 (depends on 1)

The insulin analogue of claim 1 wherein the A chain contains a substitution at position A8 that enhances affinity of the insulin analogue for the insulin receptor, optionally wherein the A8 substitution is a nitrogen-containing amino acid selected from the group Lysine, Histidine or Glutamine.

### Claim 8 (depends on 1)

The insulin analogue of claim 1 wherein the A chain contains a substitution at position A8 or position A14 that enhances thermodynamic stability of the insulin analogue for the insulin receptor, optionally wherein the substitution at position A8 or A14 is independently selected from the group consisting of His, Lys, Arg, and Glu.

### Claim 9 (depends on 1)

The insulin analogue of claim 1 wherein the A chain contains a substitution at position A21 that protects the insulin analogue from chemical degradation.

### Claim 10 (depends on 3)

The insulin analogue of claim 3 wherein said diol group at the C terminus of the B chain is an aliphatic (1, 2) diol.

### Claim 11 (depends on 3)

The insulin analogue of claim 3 wherein said diol group at the C terminus of the B chain is an aliphatic (1, 3) diol.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The insulin analogue of claim 1 where said B chain is a truncated B chain lacking residue B30, residues B29-B30, residues B28-B30, residues B27-B30 or residues B26-B30, with a diol group located at the C terminus of the truncated B chain.

### Claim 15 (depends on 1)

The insulin analogue of claim 1 where said B chain is extended by one or two amino acids with a diol group located at the C terminus of the extended B chain.

### Claim 16 (depends on 1)

The insulin analogue of claim 1 wherein
the insulin A chain is a polypeptide selected from the group consisting of
X−1X0X1IVEQX6CX8SIXIISLYQLENYCN (SEQ ID NO: 4),
X0X1IVEQX6CX8SIXIISLYQLENYCN (SEQ ID NO: 5), and
X70IVEQX6CX8SIX11SLYQLENYCN (SEQ ID NO: 83) wherein
X−1 is any amino acid, optionally wherein X−1 is Gly;
X0 is any amino acid or a modified amino acid comprising a glucose-binding element linked to its side chain;
X1 is any amino acid or a modified amino acid comprising a glucose-binding element linked to its side chain, optionally wherein X−1 is Gly;
X6 and X11 are each Cys or selenocysteine; and
X8 is Thr, His, Lys, Arg, or Glu;
X70 is a D-amino acid comprising a glucose-binding element linked to its side chain;
further wherein at least one of X−1, X0 and X1 is in the D conformation and
the insulin B chain is a polypeptide selected from the group consisting of
FVX24QHLCGSHLVEALYLVCGERGFFYTX49X50X51 (SEQ ID NO: 6), and
FVX24QHLCGSHLVEALYLVCGERGFFYTX51 (SEQ ID NO: 7), wherein
X24 is Lys or Asn;
X49 is Orn, Glu Asp, Lys, Pro, or a modified amino acid comprising a diol bearing moiety linked to the side chain of the amino acid;
X50 is Orn, Lys, Pro, or a modified amino acid comprising a diol bearing moiety linked to the side chain of the amino acid; and
X51 is Thr or a diol-bearing amino acid.

### Claim at position 17

-21. (canceled)

### Claim 22 (depends on 1)

An insulin analogue of claim 1 wherein the B chain is a polypeptide selected from the group consisting of
FVNQHLCGSHLVEALYLVCGERGFF[Sar][APD] (SEQ ID NO: 37),
FVNQHLCGSHLVEALYLVCGERGFF[dA][APD] (SEQ ID NO: 38), and
FVNQHLCGSHLVEALYLVCGERGFFYG[APD] (SEQ ID NO: 39), wherein APD is 3-amino-1,2-propandiol.

### Claim 23 (depends on 1)

An insulin analogue of claim 1 wherein the glucose-binding element contains two or more boron atoms, optionally containing phenyl-boronic acid or a halogen-modified phenyl boronic acid, such that one or more moieties is selected from the following:

### Claim 24 (depends on 1)

An insulin analogue of claim 1 wherein the insulin analogue is a “flipped” insulin analogue comprising a boron-containing glucose-binding element linked at or near the C terminus of the B chain while one or more diol groups are linked at or near the N terminus of the A chain, defined as residues A−1, A0 or A1.

### Claim 25

A method of preparing an analogue by means of trypsin-mediated semi-synthesis comprising (a) introducing an optional A-chain modification within a des-octapeptide[B23-B30] fragment of insulin or an insulin analogue and (b) introducing a diol-containing B-chain modification within a synthetic peptide of length 5-10 amino-acid residues whose N-terminal residue is Glycine and which upon modification contains no tryptic cleavage site.

### Claim 26 (depends on 25)

The method of claim 25 wherein the des-octapeptide[B23-B30] fragment of insulin or an insulin analogue is obtained by trypsin digestion of a parent insulin or insulin analogue.

### Claim 27 (depends on 25)

A method of claim 25 wherein the des-octapeptide[B23-B30] fragment of insulin or insulin analogue is obtained by trypsin digestion of a single-chain polypeptide (such as proinsulin, a proinsulin analogue or a corresponding mini-proinsulin containing a foreshortened or absent C domain) as expressed in Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris or other microbial system for the recombinant expression of proteins.

### Claim 28

(canceled)

### Claim 29

(canceled)
